Latest news with #InfluenzaMarket
Yahoo
3 days ago
- Health
- Yahoo
Influenza Market Analysis Report 2025 with Forecast to 2029: Government Support and Funding for Novel Therapies and Diagnosis Fueling Developments
Global Influenza Market to Hit USD 12.8 Billion by 2029: A Comprehensive AnalysisThe global influenza market, valued at USD 9 billion in 2024, is anticipated to grow at a CAGR of 7.2%, reaching USD 12.8 billion by 2029. This growth is driven by the vaccine segment, the most effective preventive measure against influenza's severe effects. The report offers a thorough examination of market trends, including vaccines, diagnostics, and therapeutics, with insights into regional dynamics and competitive landscapes. Key players such as Danaher Corp., Sanofi, and Abbott are highlighted, alongside detailed analyses using Porter's Five Forces and PESTLE models. SEO keywords include global influenza market, influenza vaccines, diagnostics, and market growth. Influenza Market Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Influenza Market 2025" report has been added to Influenza Market was valued at USD 9 Billion in 2024, and is projected to reach USD 12.8 Billion by 2029, rising at a CAGR of 7.2%. The vaccines segment dominated the global influenza market in 2023. Because influenza vaccines are the most effective method for lowering the risk of contracting influenza and suffering its subsequent effects, the market for this segment is growing. Influenza comes in four varieties: A, B, C and D. Seasonal epidemics are caused by the infectious influenza A and B viruses. Most people recover from fever and other symptoms within a week without medical intervention. Nevertheless, influenza can result in fatalities or severe illness, particularly in high-risk populations. Seasonal influenza spreads quickly and easily in crowded places like schools and nursing homes, so receiving a vaccination as soon as possible is critical. Based on vaccine type, the segment is further subdivided into inactivated and liveattenuated market for influenza diagnostics has been segmented into rapid tests and conventional lab tests based on diagnostic type. Increased R&D efforts are being made to detect and diagnose influenza more accurately due to its increasing global prevalence. Research is focusing on developing quicker and more precise diagnostic tools for influenza viruses, which will expand the drugs approved for influenza treatments are discussed in the therapeutic segment. These medications may lessen the likelihood of complications, lessen the severity of symptoms and shorten the course of the illness. These drugs include oseltamivir (Tamiflu), zanamivir (Relenza), peramivir (Rapivab) and baloxavir marboxil (Xofluza).Report ScopeThis report presents qualitative and quantitative data on the current dynamics impacting the global influenza market. It examines the history of various flu pandemics, disease burden and vaccine coverage in several countries. The report thoroughly evaluates the market for influenza vaccines, therapeutics and of the most popular products, clinical trials, new product approvals and emerging technologies are also included in the report. The demographics of the major regions - North America, Europe and Asia-Pacific - and their growth prospects are summarized. The profiles of leading companies and the strategies of international businesses involved in the influenza sector are also market size for influenza is categorized into three product segments: vaccines, therapeutics and diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. Diagnostics are divided into rapid and conventional lab tests. Additional growth potential and forecast data are addressed for the influenza market in each product segment for every market estimates, data are provided for 2023 as the base year, 2024 as the estimated year and forecast from 2025 through report includes: 55 data tables and 70 additional tables An updated overview and in-depth analysis of the global influenza market Analyses of the global market trends, with sales data from 2021-2024, and projections of compound annual growth rates (CAGRs) through 2029 Estimates of the actual market size and revenue forecasts, and a corresponding market share analysis by product segment, and region Discussion of the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus and human metapneumovirus (hMPV) Analysis of the market opportunities through the Porter's Five Forces model and PESTLE analysis, taking into consideration the prevailing micro- and macro environmental factors Insight into the influenza industry structure, government regulations, and key development issues Analysis of the key patent grants and IP aspects A discussion of the industry's ESG challenges and practices of the industry Analysis of the competitive landscape, featuring the leading participants, their current market rankings, and their market shares Profiles of the leading companies, including Danaher Corp., Sanofi, CSL, La Roche Ltd., and Abbott Key Attributes: Report Attribute Details No. of Pages 188 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $9 Billion Forecasted Market Value (USD) by 2029 $12.8 Billion Compound Annual Growth Rate 7.2% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Overview Pandemic Scenario Porter's Five Forces Analysis in the Influenza Vaccines Market Supply Chain Analysis Vaccine Development Vaccine Manufacturing Storage and Inventory Management Distribution Administration and Immunization Macroeconomic Factors Analysis Impact of U.S.-China Trade War Global Economic Growth Demographic Trends Public Health Crises and Pandemics Chapter 3 Market Dynamics Market Dynamics Key Takeaways Market Drivers Development of Rapid Tests and Molecular Technologies Government Support and Funding for Novel Therapies and Diagnosis Rising Public Awareness About Flu Vaccines Market Restraints Therapeutic Market Dominated by Limited Suppliers High Cost Associated with Storage and Supply of Flu Vaccines Market Opportunities Robust Pipeline of Influenza Vaccines Demand for Improved Prevention, Treatment and Vaccine Accessibility Chapter 4 Regulatory Landscape Overview Regulatory Aspects of Influenza Vaccines Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. Influenza Season Influenza Vaccines Approved by EMA Regulatory Scenario of Influenza Drugs Approval Process of Influenza Detection Kit Sensitivity Specificity Chapter 5 Emerging Trends and Pipeline Analysis Overview Advance in Influenza Diagnosis SHINE Technology Electrochemical Biosensors Wearable Lab-on-a-Chip Devices Quantum Dots and Fluorescent Nanoparticles Role of AI in Influenza Diagnosis Emerging Technologies in Influenza Vaccines Universal Influenza Vaccine mRNA-based Influenza Vaccines Nanotechnology-based Vaccines Patch-based Vaccines Advances in Influenza Therapeutics Nanoparticle-based Therapies Potential Drug Agents in Clinical Trials Patent Analysis Key Takeaways Chapter 6 Market Segmentation Analysis Segmentation Breakdown Global Influenza Market by Product Segment Influenza Diagnostics Influenza Vaccines Influenza Therapeutics Geographic Breakdown Key Takeaways North America Europe Asia-Pacific Rest of World Chapter 7 Competitive Intelligence Company Share Analysis of the Influenza Vaccines Market Company Share Analysis of Influenza Diagnostics Market Company Share Analysis of Influenza Therapeutics Market Venture Fundings and Investments Landscape Key Developments in Market Chapter 8 Sustainability in Influenza Market: ESG Perspective Overview ESG Risk Ratings Conclusion Chapter 9 AppendixCompanies Featured Abbott AstraZeneca BD Biocryst Pharmaceuticals Inc. CSL Daiichi Sankyo Co. Ltd. Danaher Corp. F. Hoffmann-La Roche Ltd. GSK PLC Hologic Inc. Quidelortho Corp. Sanofi Sekisui Diagnostics Thermo Fisher Scientific Inc. Viatris Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Influenza Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
3 days ago
- Health
- Yahoo
Influenza Market Analysis Report 2025 with Forecast to 2029: Government Support and Funding for Novel Therapies and Diagnosis Fueling Developments
Global Influenza Market to Hit USD 12.8 Billion by 2029: A Comprehensive AnalysisThe global influenza market, valued at USD 9 billion in 2024, is anticipated to grow at a CAGR of 7.2%, reaching USD 12.8 billion by 2029. This growth is driven by the vaccine segment, the most effective preventive measure against influenza's severe effects. The report offers a thorough examination of market trends, including vaccines, diagnostics, and therapeutics, with insights into regional dynamics and competitive landscapes. Key players such as Danaher Corp., Sanofi, and Abbott are highlighted, alongside detailed analyses using Porter's Five Forces and PESTLE models. SEO keywords include global influenza market, influenza vaccines, diagnostics, and market growth. Influenza Market Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Influenza Market 2025" report has been added to Influenza Market was valued at USD 9 Billion in 2024, and is projected to reach USD 12.8 Billion by 2029, rising at a CAGR of 7.2%. The vaccines segment dominated the global influenza market in 2023. Because influenza vaccines are the most effective method for lowering the risk of contracting influenza and suffering its subsequent effects, the market for this segment is growing. Influenza comes in four varieties: A, B, C and D. Seasonal epidemics are caused by the infectious influenza A and B viruses. Most people recover from fever and other symptoms within a week without medical intervention. Nevertheless, influenza can result in fatalities or severe illness, particularly in high-risk populations. Seasonal influenza spreads quickly and easily in crowded places like schools and nursing homes, so receiving a vaccination as soon as possible is critical. Based on vaccine type, the segment is further subdivided into inactivated and liveattenuated market for influenza diagnostics has been segmented into rapid tests and conventional lab tests based on diagnostic type. Increased R&D efforts are being made to detect and diagnose influenza more accurately due to its increasing global prevalence. Research is focusing on developing quicker and more precise diagnostic tools for influenza viruses, which will expand the drugs approved for influenza treatments are discussed in the therapeutic segment. These medications may lessen the likelihood of complications, lessen the severity of symptoms and shorten the course of the illness. These drugs include oseltamivir (Tamiflu), zanamivir (Relenza), peramivir (Rapivab) and baloxavir marboxil (Xofluza).Report ScopeThis report presents qualitative and quantitative data on the current dynamics impacting the global influenza market. It examines the history of various flu pandemics, disease burden and vaccine coverage in several countries. The report thoroughly evaluates the market for influenza vaccines, therapeutics and of the most popular products, clinical trials, new product approvals and emerging technologies are also included in the report. The demographics of the major regions - North America, Europe and Asia-Pacific - and their growth prospects are summarized. The profiles of leading companies and the strategies of international businesses involved in the influenza sector are also market size for influenza is categorized into three product segments: vaccines, therapeutics and diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. Diagnostics are divided into rapid and conventional lab tests. Additional growth potential and forecast data are addressed for the influenza market in each product segment for every market estimates, data are provided for 2023 as the base year, 2024 as the estimated year and forecast from 2025 through report includes: 55 data tables and 70 additional tables An updated overview and in-depth analysis of the global influenza market Analyses of the global market trends, with sales data from 2021-2024, and projections of compound annual growth rates (CAGRs) through 2029 Estimates of the actual market size and revenue forecasts, and a corresponding market share analysis by product segment, and region Discussion of the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus and human metapneumovirus (hMPV) Analysis of the market opportunities through the Porter's Five Forces model and PESTLE analysis, taking into consideration the prevailing micro- and macro environmental factors Insight into the influenza industry structure, government regulations, and key development issues Analysis of the key patent grants and IP aspects A discussion of the industry's ESG challenges and practices of the industry Analysis of the competitive landscape, featuring the leading participants, their current market rankings, and their market shares Profiles of the leading companies, including Danaher Corp., Sanofi, CSL, La Roche Ltd., and Abbott Key Attributes: Report Attribute Details No. of Pages 188 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $9 Billion Forecasted Market Value (USD) by 2029 $12.8 Billion Compound Annual Growth Rate 7.2% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Overview Pandemic Scenario Porter's Five Forces Analysis in the Influenza Vaccines Market Supply Chain Analysis Vaccine Development Vaccine Manufacturing Storage and Inventory Management Distribution Administration and Immunization Macroeconomic Factors Analysis Impact of U.S.-China Trade War Global Economic Growth Demographic Trends Public Health Crises and Pandemics Chapter 3 Market Dynamics Market Dynamics Key Takeaways Market Drivers Development of Rapid Tests and Molecular Technologies Government Support and Funding for Novel Therapies and Diagnosis Rising Public Awareness About Flu Vaccines Market Restraints Therapeutic Market Dominated by Limited Suppliers High Cost Associated with Storage and Supply of Flu Vaccines Market Opportunities Robust Pipeline of Influenza Vaccines Demand for Improved Prevention, Treatment and Vaccine Accessibility Chapter 4 Regulatory Landscape Overview Regulatory Aspects of Influenza Vaccines Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. Influenza Season Influenza Vaccines Approved by EMA Regulatory Scenario of Influenza Drugs Approval Process of Influenza Detection Kit Sensitivity Specificity Chapter 5 Emerging Trends and Pipeline Analysis Overview Advance in Influenza Diagnosis SHINE Technology Electrochemical Biosensors Wearable Lab-on-a-Chip Devices Quantum Dots and Fluorescent Nanoparticles Role of AI in Influenza Diagnosis Emerging Technologies in Influenza Vaccines Universal Influenza Vaccine mRNA-based Influenza Vaccines Nanotechnology-based Vaccines Patch-based Vaccines Advances in Influenza Therapeutics Nanoparticle-based Therapies Potential Drug Agents in Clinical Trials Patent Analysis Key Takeaways Chapter 6 Market Segmentation Analysis Segmentation Breakdown Global Influenza Market by Product Segment Influenza Diagnostics Influenza Vaccines Influenza Therapeutics Geographic Breakdown Key Takeaways North America Europe Asia-Pacific Rest of World Chapter 7 Competitive Intelligence Company Share Analysis of the Influenza Vaccines Market Company Share Analysis of Influenza Diagnostics Market Company Share Analysis of Influenza Therapeutics Market Venture Fundings and Investments Landscape Key Developments in Market Chapter 8 Sustainability in Influenza Market: ESG Perspective Overview ESG Risk Ratings Conclusion Chapter 9 AppendixCompanies Featured Abbott AstraZeneca BD Biocryst Pharmaceuticals Inc. CSL Daiichi Sankyo Co. Ltd. Danaher Corp. F. Hoffmann-La Roche Ltd. GSK PLC Hologic Inc. Quidelortho Corp. Sanofi Sekisui Diagnostics Thermo Fisher Scientific Inc. Viatris Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Influenza Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
